为每个患者量身定做个体化的卵巢刺激方案是非常具有挑战性的,由于不同患者之间的卵巢应答会有极大的不同。遗传药理学的出现开创了以单个患者遗传易感性(geneticpredisposition)为基础改善用药合理和不合理之间平衡的新研究领域。临床研究显示FSH受体基因p.N680S的多态性决定 Tailor-made individualized ovarian stimulation regimens for each patient can be very challenging, as ovarian responses vary greatly from patient to patient. The emergence of pharmacogenetics opens up new fields of research that improve the balance between reasonable and unreasonable use of medication based on the genetic predisposition of a single patient. Clinical studies have shown that the FSH receptor gene p.N680S polymorphism